Pharming Group Reports 21% Revenue Growth in Q3 2026 Driven by RUCONEST and Joenja
Pharming Group N.V. reported strong third-quarter results for 2026, with total revenue reaching $117.6 million, a 21% increase year-over-year. Growth was primarily fueled by the stabilization of RUCONEST global revenue and a significant 58% surge in Joenja revenue, supported by patient expansion in the U.S. and new international market launches. The company demonstrated improved profitability, with operating profit rising 89% year-over-year to $29.9 million. Management also adjusted its full-year guidance downward for operating expenses due to structural savings, while maintaining a robust revenue outlook of $380 million to $390 million. Despite these gains, leadership noted potential headwinds including inventory timing shifts and an upcoming oral competitor expected in 2027.
Tickers: $PHAR
Topics: Financial Guidance Operating Profit Pharmaceuticals Revenue Growth
Read the full article at Motley Fool
Part of the story Freedom Financial Holdings Reports Q3 2026 Earnings Growth and Increases Share Repurchase Authorization (27 articles)